SCID/NOD mice model for 5-FU induced intestinal mucositis: Safety and effects of probiotics as therapy

Autor: Chun-Yan Yeung, Jen-Shiu Chiang Chiau, Hung-Chang Lee, Wai-Tao Chan, Mei-Lien Cheng, Chuen-Bin Jiang, Szu-Wen Chang, Lawrence Huang
Rok vydání: 2019
Předmět:
Zdroj: Pediatrics and Neonatology, Vol 60, Iss 3, Pp 252-260 (2019)
ISSN: 1875-9572
DOI: 10.1016/j.pedneo.2018.07.007
Popis: Background: For chemotherapy patients, intestinal mucositis is a frequent complication. Previously, we evaluated the beneficial effect of oral probiotics in 5-Fluorouracil (5-FU) induced mucositis in BALB/c mice. Here, we used SCID/NOD mice instead to simulate the immunodeficiency of chemotherapy patients: first, to evaluate the safety of probiotic supplementation and second, to determine the probiotic effect in response to 5-FU intestinal mucositis. Methods: Thirty-six SCID/NOD mice were injected with saline (three control groups) or 5-FU (three experimental groups) intraperitoneally daily for five days. Mice were given either oral saline daily, probiotic suspension of Lactobacillus casei variety rhamnosus (Lcr35, Antibiophilus™, France) or Lactobacillus acidophilus and Bifidobacterium bifidum (LaBi, Infloran™, Italy). Blood, liver, spleen, and lymph node tissue samples were evaluated for probiotic translocation via culture and Q-PCR. Weight change, diarrhea score, jejunal villus height (VH) and crypt depth (CD), and serum cytokine levels of TNF-α, IFNγ, IL-1β, IL-6, IL-4, IL-10, IL-13, and IL-17 were also assessed. Results: No weight loss was found in the SCID control group. Mean weight loss of 10.63 ± 0.87% was noted by day five in 5-FU group without probiotics but it was only 6.2 ± 0.43% if mice were given Lcr35 (p
Databáze: OpenAIRE